BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Roche has put forward a new approach to genetic analysis, which it describes as sequencing-by-expansion—a proprietary method ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology company specializing in the development of allogeneic CAR T cell therapies, stands at a critical juncture in its journey to bring innovative ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

A GROUNDBREAKING study has revealed how the human immune system evolves across the lifespan, uncovering age-specific changes ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision ...

Researchers have discovered the mechanism that helps regulate the immune system’s response to helminth infection.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Auron Therapeutics has raised a $27 million Series B financing that it will use to initiate clinical development of its lead experimental drug, AUTX-703, in blood cancers.

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...